KEYNOTE-942 at ASCO: 5 Years With a Personalized mRNA Vaccine for Melanoma

Andrew L. Pecora, MD, of Hackensack Meridian Health John Theurer Cancer Center, reflects on the latest data from KEYNOTE-942, a trial comparing the mRNA-based cancer vaccine intismeran autogene combined with pembrolizumab (Keytruda) vs pembrolizumab alone. The vaccine is individually tailored by parallel sequencing a patient’s normal DNA against their tumor’s DNA. By isolating mutated genetic regions, a sophisticated algorithm determines which proteins will most effectively augment a patient’s natural immune response. The resulting individualized mRNA is encapsulated and administered via a routine injection alongside standard immunotherapy.

The rationale for combining this personalized vaccine with the anti-PD-1 inhibitor pembrolizumab builds directly upon the current standard of care. While traditional frontline immunotherapy significantly improves survival compared to observation, it is only effective in about 50% of advanced melanoma cases. Pecora explains that combining the personalized vaccine with pembrolizumab successfully broadens and deepens the patient’s immune repertoire, turning a partial immune response into a robust clinical defense mechanism.

The clinical data from this study continues to support this synergistic approach. In a long-term update tracking outcomes out to 5 years, the regimen sustained the striking efficacy trends originally observed in the primary two-year and three-year analyses. Now, at 5 years, the addition of the vaccine to pembrolizumab resulted in an approximate 49% improvement in recurrence-free survival, meaning significantly more patients remained completely free of disease progression compared with those treated with pembrolizumab alone.

This heightened efficacy did not come at the cost of patient safety. The long-term safety profile of the vaccine-immunotherapy combination showed no new or worsening safety signals when compared directly to the historical safety data of immunotherapy monotherapy. Pecora notes that given the massive effect size observed, the next step is moving the regimen through confirmatory trials to secure formal regulatory approval, with the hope that it will become a new standard of care.

Ultimately, this study highlights a broader, defining theme in modern oncology: transitioning away from traditional chemotherapy and toward biological therapies that harness and optimize the patient’s own immune system.